According to CNBC, U.S. District Judge K. Michael Moore of the Southern District of Florida dismissed most of the lawsuits against celebrities such as Tom Brady, Gisele Bündchen, Kevin O’Leary, Stephen Curry, and several YouTube influencers. These celebrities were accused of improperly promoting the now-bankrupt FTX exchange. In the ruling, the judge stated that the plaintiffs (a group of FTX investors) failed to prove that these promoters were aware of the fraudulent activities of FTX and its CEO Sam Bankman-Fried (SBF) in advance. The FTX collapse in November 2022 resulted in billions of dollars in customer losses and triggered global regulatory investigations. The core issue of the lawsuit was that these celebrities received millions of dollars in promotional fees without disclosing their financial interests, allegedly violating federal and state advertising laws. The court ultimately determined that the existing evidence was insufficient to hold them legally accountable. However, state law claims against some defendants can still proceed.
Judge Rules Stephen Curry, Tom Brady, and Other Celebrities Not Liable for Most FTX Investor Claims
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
